roadmap upcom piii orion readout
orion piii trial read late-break set
esc septemb think unlik benefit deterior piii
expect reduct compar trial also expect clean
safeti profil mirror market drug likelihood good data look high
potenti stock price upsid prospect failur look low
downsid
similar efficaci antibodi achiev inclisiran robust durabl
effect inclisiran ldl-c reduct demonstr long-term
extens studi place efficaci twice-a-year dose inclisiran par
mab twice-a-month schedul cross-trial analysi target
therapeut reveal size ldl-c reduct effect preserv
piii studi management set expect ldl-c reduct three piii trial
base dose-respons model develop data think look
safeti profil still look clean given long-term natur ldl-c lower treatment
safeti key inclisiran adopt clinic date seven dsmb review
conduct without report consider safeti concern trial
recommend continu plan inclisiran well toler
trial mild moder well balanc treatment
placebo group clean safeti profil reinforc extens
studi follow patient three year pool analysi focus
renal impair patient new safeti issu observ either analysi
see stock react data mdco share rebound
low earli think investor expect reduct low-to-
mid rang across day time-weight averag co-primari endpoint
rel clean safeti profil scenario think stock move high
scenario would expect mdco share declin scenario
modest reduct involv reduct rang profil
would seen inferior mab howev cvot reduct per analysi could
still achiev superior benefit think stock would
reduct less worst-cas scenario efficaci estim
likelihood howev stock could scenario
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
approv blockbust sale inclisiran us
begin
ex-u royalti inclisiran begin
in-licens addit pipelin asset
approv blockbust sale inclisiran us
rapid uptak posit market leader
categori
in-licens least one new pipelin asset
inclisiran develop unsuccess ascvd and/
result inferior exist inhibitor
in-licens addit pipelin asset
model blockbust sale inclisiran us revenu
billion risk-adjust
model ex-u royalti inclisiran million
risk-adjust
top-lin data readout pivot piii trial
inclisiran ascvd hefh
ye nda file inclisiran
expect us approv launch inclisiran
readout cvot trial risk reduct
mace ascvd
pleas see import disclosur inform page report
three pivot piii trial track data readout
piii studi evalu efficaci safeti inclisiran lower
ldl-c level subject elev ldl-c despit maximum toler dose ldl-
c-lower therapi focus ascvd pt baselin ldl-c
level hefh serum ldl-c subcutan
inject inclisiran administ day day everi six month thereaft
patient need maxim toler dose statin unless document evid
intoler without stabl dose lipid-low therapi co-primari
endpoint percentag chang ldl-c baselin day time-adjust
percentag chang ldl-c level baselin day day three
trial complet enrol six week apart given
trial period data readout expect base dose-respons model built
data valid mdco project ldl-c reduct day
time-averag ldl-c reduct three piii trial tabl
tabl simul result piii efficaci readout base dose-pd respons model
ldl-c lower effect inclisiran slightli inferior
mab short-term in-lin long-term
recal trial inclisiran doubl dose achiev reduct ldl-
 baselin ldl-c level day result slightli lower
effect seen two approv mab ldl-c level decreas
week regn/sni praluent week amgn repatha tabl
note mab studi use calcul ldl-c level deriv friedewald
equat wherea mdco measur ldl-c level directli
ultracentrifug demonstr multipl studi friedewald
calcul often underestim ldl-c level one population-bas lipid profil studi
peopl martin ss et al jacc show friedewald-
estim ldl-c level lower measur ldl-c level absolut
level ldl-c low tg level level
patient usual arriv mab inclisiran treatment lower readout
calcul ldl-c turn enlarg differ baselin overst ldl-c
reduct therefor inclisiran efficaci theori could higher
report calcul ldl-c instead measur ldl-c
pleas see import disclosur inform page report
ldl-c ldl-c reduct day time averag ldl-c absolut ldl-c reduct absolut time averag ldl-c base dose-pd respons model equiti research
longer term inclisiran effect maintain demonstr
extens trial patient roll treatment arm continu receiv
inclisiran everi six month three year inclisiran treatment achiev
reduct ldl-c month start reach time-averag
absolut reduct patient roll group
demonstr reduct ldl-c level togeth result place
long-term efficaci inclisiran line repatha parluent achiev
ldl-c level reduct year week respect tabl
tabl cross-trial comparison efficaci target therapeut
clinicaltri gov trial id note trial row
project result base data compar multipl trial antibodi
correspond studi analysi reveal effect ldl-c reduct
consist give us confid similar ldl-c lower effect
orion trial seen tabl
tabl comparison ldl-c reduct baselin studi
clinicaltri gov trial id note chart
data date suggest clean safeti profil
safeti concern rais seven dsmb review latest interim analysi
conduct juli trial recommend continu plan inclisiran
well toler trial advers event mild moder well
balanc placebo treatment group ast/alt elev uln observ
patient treat inclisiran compar rate patient treat
placebo line number observ trial mab
pleas see import disclosur inform page report
statinsst statinsmtd statin other other other baselin ldl-c level ldl-c reduct baselin absolut reduct ldl-c level ldl-c reduct baselin long baselin total-c level total-c reduct baselin hdl-c level non-hdl-c reduct baselin apob level apob reduct lipid-low therapiesldl-coth lipid marker equiti research
safeti profil remain clean extens studi three year
new report particular concern relat rnai technolog includ lft
elev liver tox renal tox myalgia elev thrombocytopenia check
none deem relat inclisiran sinc renal impair common
co-morbid ascvd patient increas risk mdco conduct pool analysi
pi renal impair patient patient stratifi renal
function suggest increas risk patient sever renal impair even
though plasma exposur inclisiran increas two-fold popul
howev increas exposur transient clear within hour dose
accumul inclisiran plasma suggest addit safeti issu
less like occur dose repeatedli biannual schedul data warrant
inclus patient sever renal impair on-going piii trial
mab set high safeti bar inclisiran reach
mab well toler multipl larg trial patient
treat common teae inject site reaction nasopharyng influenza
given long-term natur ldl-c lower treatment clean safeti profil larg
cohort repeat dose follow long time extrem import
elev ae rate addit safeti concern could potenti increas physician hesit
adopt inclisiran ldl-c lower regimen patient current avail
safeti data inclisiran still limit small sampl size repeat dose inject
eagerli await result on-going piii trial fill gap
note analysi renal impair patient done small sampl size sever
renal function impair singl inject inclisiran worth follow
larger cohort receiv repeat dose confirm similar safeti profil
obtain similar caution also taken patient sever heart failur
 orion trial expand includ nyha class ii patient regardless left
ventricular ef compar studi
inclisiran evalu benefit cv risk
reduct outcom trial
associ high level ldl-c increas risk cv mortal morbid
well establish decad research cvot trial conduct
mab fourier evalu repatha patient stabl cardiovascular diseas
median year odyssey outcom assess praluent patient recent
acut coronari syndrom median follow-up mab achiev
similar reduct risk major advers cardiovascular event mace includ death
coronari heart diseas myocardi infarct stroke hospit unstabl
angina suggest possibl inclisiran reach compar effect reduc
risk cardiovascular event fourier trial enrol pt baselin mg/dl
wherea odyssey outcom enrol pt baselin ldl-c mg/dl
post-hoc analysi odyssey outcom pt baselin mg/dl report
mace reduct median year follow-up addit risk cv death
all-caus death declin respect
comparison mdco enrol pt mg/dl follow patient
year therefor better likelihood see meaning improv
pleas see import disclosur inform page report
compar fourier odyssey outcom mdco current recruit patient
pre-exist atherosclerot cardiovascular diseas similar fourier trial
baselin mg/dl median follow-up piii outcom trial
evalu efficaci inclisiran lower risk heart attack
stroke enrol expect complet year data avail ye
minim ldl-c reduct requir
inclisiran achiev similar outcom evolocumab
key question whether inclisiran could achiev superior outcom reduc cv risk
mab project outcom cvot trial inclisiran assum
baselin ldl-c level mg/dl assum year follow-up think
reduct lead mace improv high incorpor
discount tabl even reduct phase come lower
estim cvot outcom benefit could still may question
expect better outcom vs current mab point higher
level baselin number year follow-up cvot
design follow patient year meta-analysi paper et al eur heat
report cv benefit statin therapi per mmol/l ldl-c lower
year treatment respect data alon
would like seen benefit mab follow-up last
four year patient
tabl scenario analysi outcom
arriv pt base dcf valuat model includ sale estim
inclisiran pt assum discount rate termin growth rate
outstand share million inclisiran estim us sale billion risk-
adjust ex-u royalti million risk-adjust
pleas see import disclosur inform page report
clinic failur compani biotechnolog pharmaceut develop
treatment futur clinic failur lead delay approv possibl
discontinu program
regulatori failur fda could determin compani nda inadequ could
delay approv delay approv timelin could impact earn estim price
commerci failur estim may reli success company/partn
receiv drug reimburs private/publ medic insur payer
financ risk mdco may need rais addit fund support sg
activ current includ estim addit equiti rais howev
pleas see import disclosur inform page report
pleas see import disclosur inform page report
medicin companyincom statement valu mm except ep fy fy fy fy fy fy fy fy fy fy fy fy fy revenu net product sale inclisiran inclisiran royalti ex-u total revenu expens impair research sale gener royalti expens inclisiran- mileston payment inclisiran- total cost incom loss incom expens legal settlement- co-promot loss short-term investment- loss sale assets- interest incom incom total incom pre-tax incom provis benefit incom net incom amount attribut mdco loss continu loss discontinu oper net net incom loss attribut ep basic loss earn per common share attribut mdco loss earn continu loss earn discontinu basic loss earn per dilut loss earn per common share attribut mdco loss earn continu loss earn discontinu dilut loss earn per weight averag share weight averag share sourc compani data jefferi medicin companydiscount analysi valu capit chang work free cash compani data jefferi estim equiti research
medicin compani global pharmaceut compani provid variou medicin hospit advanc treatment
critic care patient primarili unit state europ market angiomax intraven direct thrombin inhibitor use
anticoagul combin aspirin patient unstabl angina undergo percutan translumin coronari
angioplasti use patient undergo percutan coronari intervent cleviprex intraven small molecul
calcium channel blocker reduct blood pressur
pt dcf base risk includ clinic regulatori commerci
price target base appli histor industri multipl non-gaap ep support
dcf risk includ ip litig biosimilar price competit
pt dcf-base discount rate tg risk includ commerci regulatori clinic
valuat price base blend price-to-earnings npv assum discount sector pe discount
npv sum-of-the-part valuat risk regulatori price manufactur praluent dual elig
biren amin certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
kelli shi phd certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
chang liu phd certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
jeet mukherje phd certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
